✦ LIBER ✦

Patients with a Non-dysferlin Miyoshi Myopathy have a Novel Membrane Repair Defect

✍ Scribed by Jyoti K. Jaiswal; Gareth Marlow; Gillian Summerill; Ibrahim Mahjneh; Sebastian Mueller; Maria Hill; Katsuya Miyake; Hannelore Haase; Louise V. B. Anderson; Isabelle Richard; Sari Kiuru-Enari; Paul L. McNeil; Sanford M. Simon; Rumaisa Bashir

Book ID: 111268202
Publisher: John Wiley and Sons
Year: 2006
Tongue: English
Weight: 642 KB
Volume: 8
Category: Article
ISSN: 1398-9219
DOI: 10.1111/j.1600-0854.2006.00505.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Dysferlin mutation analysis in a group o

Dysferlin mutation analysis in a group of Italian patients with limb-girdle muscular dystrophy and Miyoshi myopathy

✍ K. Kawabe; K. Goto; I. Nishino; C. Angelini; Y. K. Hayashi 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 238 KB

G.P.4.10 Functional evaluation of a puta

G.P.4.10 Functional evaluation of a putative mini-dysferlin identified in a patient with moderate Miyoshi myopathy phenotype

✍ M. Krahn; N. Wein; K. Nguyen; C. Vial; S. Courrier; W. Lostal; M. Bartoli; V. La 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 47 KB

Comparative Outcomes of Augmented versus

Comparative Outcomes of Augmented versus Non-Augmented Anterior Defect Repair in Patients with Symptomatic Pelvic Organ Prolapse

✍ Buscaglia, N.; March, W.; Amey, A.; Postlethwaite, D.; Cho, M.; Morrill, M. 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 173 KB

Phase 1b study results of IMO-2055, a no

Phase 1b study results of IMO-2055, a novel TLR9 agonist, in combination with erlotinib (E) and bevacizumab (bev) in patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC) who have progressed following prior chemotherapy

✍ Smith, David A.; Conkling, Paul; Richards, Donald A.; Flores, Maria Regina C.; N 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 53 KB